Candriam SCA’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.99M | Sell |
262,384
-326,547
| -55% | -$3.72M | 0.02% | 431 |
|
|
2025
Q1 | $7M | Sell |
588,931
-45,695
| -7% | -$543K | 0.04% | 276 |
|
|
2024
Q4 | $12M | Sell |
634,626
-427,333
| -40% | -$8.05M | 0.07% | 238 |
|
|
2024
Q3 | $23.9M | Sell |
1,061,959
-102,287
| -9% | -$2.3M | 0.14% | 152 |
|
|
2024
Q2 | $24.3M | Buy |
1,164,246
+272,136
| +31% | +$5.68M | 0.15% | 142 |
|
|
2024
Q1 | $13.1M | Sell |
892,110
-26,000
| -3% | -$382K | 0.08% | 224 |
|
|
2023
Q4 | $9.48M | Sell |
918,110
-50,000
| -5% | -$516K | 0.07% | 258 |
|
|
2023
Q3 | $7.61M | Sell |
968,110
-51,712
| -5% | -$406K | 0.05% | 260 |
|
|
2023
Q2 | $10.2M | Buy |
1,019,822
+119,734
| +13% | +$1.2M | 0.07% | 244 |
|
|
2023
Q1 | $7.36M | Buy |
900,088
+49,513
| +6% | +$405K | 0.05% | 300 |
|
|
2022
Q4 | $9.34M | Buy |
850,575
+25,000
| +3% | +$274K | 0.06% | 284 |
|
|
2022
Q3 | $10.8M | Sell |
825,575
-13,800
| -2% | -$180K | 0.08% | 255 |
|
|
2022
Q2 | $10.6M | Buy |
839,375
+74,269
| +10% | +$941K | 0.09% | 216 |
|
|
2022
Q1 | $10.7M | Sell |
765,106
-28,997
| -4% | -$406K | 0.07% | 245 |
|
|
2021
Q4 | $23M | Buy |
794,103
+239,107
| +43% | +$6.92M | 0.15% | 159 |
|
|
2021
Q3 | $16.6M | Buy |
554,996
+47,693
| +9% | +$1.43M | 0.11% | 201 |
|
|
2021
Q2 | $13.5M | Buy |
507,303
+507,290
| +3,902,231% | +$13.5M | 0.09% | 242 |
|
|
2021
Q1 | $0 | Buy |
+13
| New | – | ﹤0.01% | 814 |
|